Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7121661 + RO7247669 versus nivolumab in advanced or metastatic esophageal squamous cell carcinoma
PACTR202106740461845Phase 2Not yet recruiting
- Sponsor
- Roche
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Esophageal Squamous Cell Carcinoma (ESCC) comparing RO7121661 + RO7247669 with nivolumab (2 arms). Primary endpoint: Overall Survival. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on PACTR202106740461845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202106740461845.